Valence ロゴ
人気
ログイン

ウォッチリストに追加

Vertex Pharmaceuticals

NasdaqGS: VRTX · リアルタイム株価 · USD
528.19
+12.64 (2.45%)
終値時点： Aug 18, 2026, 3:59 PM

Vertex Pharmaceuticals (VRTX) Stock Price, Analysis & Data

2.45%
買気配530.36
時価総額133.88B
売上高（TTM）12.59B
純利益（TTM）4.41B
ベータ0.30
EPS（TTM）17.17
PER（TTM）30.76
予想PER24.21
PBR（TTM）6.61
PSR（TTM）10.63
Earnings DateNov 2, 2026
売気配521.32
出来高1,496,849
平均出来高（20日）1,567,301
始値520.00
前日終値515.55
当日レンジ517.34 - 533.78
52週レンジ374.17 - 546.17
アナリストBuy
目標株価570 (7.92%)
配当n/a
権利落ち日n/a

VRTXについて

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Jul 24, 1991
従業員数 6,400
上場取引所 NasdaqGS
ティッカー VRTX
ウェブサイト https://www.vrtx.com
企業情報の全文

業績

2025年のVertex Pharmaceuticalsの売上高は12Bで、前年の11.02Bから8.9%の増加でした。 利益は3.95Bで、-838.09%の減少でした。

財務諸表

アナリスト予想

25件のアナリスト評価によると、VRTX株の平均レーティングは「Buy」です。12か月後の目標株価は570で、直近株価から7.92%の上昇余地となります。

株価予想

決算サプライズ

Vertex PharmaceuticalsはAug 3, 2026に四半期決算を発表しました：
  • 売上高は $3.33B で、予想を下回りました $0, うち 12.45% の前年比増加にあたります.
  • EPSは 4.73 で、予想を下回りました -0.02, うち 4.65% の前年比増加にあたります.

    • 次回決算発表

    Vertex Pharmaceuticalsの決算発表予定日は Nov 2, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    14時間前 · StockStory

    3 Cash-Producing Stocks on Our Watchlist

    Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

    news image

    4日前 · Insider Monkey

    Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

    On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

    news image

    4日前 · Simply Wall St.

    Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

    Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent n...

    news image

    4日前 · Motley Fool

    Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

    The drugmaker should significantly mitigate its most important risk as it develops new products.

    news image

    4日前 · Simply Wall St.

    Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

    Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurch...

    2ページ中1ページ